Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02099864 · ClinicalTrials.gov registry record · Phase 2
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
A Phase 2 study of Castration-Resistant Prostate Carcinoma and Recurrent Prostate Carcinoma, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT02099864: Completed Phase 2 study of Castration-Resistant Prostate Carcinoma and Recurrent Prostate Carcinoma, sponsored by OHSU Knight Cancer Institute.
NCT02099864 is a Phase 2 study of Castration-Resistant Prostate Carcinoma and Recurrent Prostate Carcinoma that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 36 participants, below the 77-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (53% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02099864, a Phase 2 study of Castration-Resistant Prostate Carcinoma and Recurrent Prostate Carcinoma, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies genetic and molecular mechanisms in assessing response in patients with prostate cancer receiving enzalutamide therapy. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amount of androgens made by the body. Studying samples of tissue and blood in the laboratory from patients with prostate cancer may help doctors better understand castration-resistant prostate cancer. It may also help doctors make improvements in prostate cancer treatment.
Primary Outcome
The percentage of participants with a \>= 50% decline in PSA values will be reported with 95% exact confidence interval. For each participant, percentage decline in PSA values are calculated as 100% times the difference between PSA values taken at baseline and 12 weeks divided by PSA values at baseline. Percentage of participants determined as 100% times the number of participants with \>= 50% decline divided by overall number of participants.
Conditions Studied
Interventions
- DRUG Enzalutamide
Study Locations (2)
California
- UCSF Medical Center-Mount Zion - San Francisco
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-02-05 |
| Est. Completion | 2024-07-08 |
| Phase | Phase 2 |
What the finished NCT02099864 record still lists
NCT02099864 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 77-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (53% lower).
The record links to 7 conditions, with Castration-Resistant Prostate Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Enzalutamide is the first listed.
NCT02099864 reports a single indexed study location in California, Oregon.
Frequently Asked Questions
What is clinical trial NCT02099864 about?
NCT02099864 is a clinical study titled "Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy". This phase II trial studies genetic and molecular mechanisms in assessing response in patients with prostate cancer receiving enzalutamide therapy. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amount of androgens made by the body....
What is the current status of trial NCT02099864?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2014-02-05. Estimated completion is 2024-07-08.
What conditions does trial NCT02099864 study?
This clinical trial studies the following conditions: Castration-Resistant Prostate Carcinoma, Recurrent Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Metastatic Malignant Neoplasm in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7.
What interventions are being tested in trial NCT02099864?
The interventions under investigation include: Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT02099864?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02099864 being conducted?
This trial has 2 study locations across California, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Castration-Resistant Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02099864's enrollment target sits among peer trials
36 24th of 43 higher than 19 of 43 other Castration-Resistant Prostate Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Castration-Resistant Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
RECRUITING · Phase 2
-
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
RECRUITING · Phase 2
-
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
RECRUITING · Phase 2
-
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
RECRUITING · Phase 2
-
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI